ADA and type 2 diabetes mellitus: Before the use of DPP-4 inhibitors for the treatment of type 2 diabetes, DPP-4 had been intensively studied as an immune regulator because it acts as a T cell costimulator and a binding partner of adenosine deaminase (ADA) [9].